MedTrace Logo

Temozolomide 12 Cycles Versus 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma.

NCT02209948 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 166

Last updated 2021-01-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to show if prolonging treatment with temozolomide to 12 cycles improve progression-free survival in patients with glioblastoma included in this study, randomized according to o6-methylguanine-DNA-methyltransferase (MGMT) methylation status and residual disease or not, to receive an additional 6 cycles of temozolomide.

Conditions

Interventions

DRUG

Temozolomide

Sponsors & Collaborators

  • Grupo Español de Investigación en Neurooncología

    lead OTHER

Principal Investigators

  • Carmen Balañá, M.D. · Hospital Germans Trias i Pujol - ICO Badalona

  • Mª Ángeles Vaz, M.D. · Hospital Universitario Ramon y Cajal

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-22
Primary Completion
2019-06-30
Completion
2019-06-14

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02209948 on ClinicalTrials.gov